Sustained Effect of Botulinum Neurotoxin in Myoclonus Owing to Epilepsia Partialis Continua

Overview

Journal Mov Disord Clin Pract

Publisher Wiley

Specialty Neurology

Date 2019 Mar 7

PMID 30838240

Authors

Janis Rebecca Bedarf

Milena Marek

Christian G Bien

Christian E Elger

Sebastian Paus

Affiliations

Soon will be listed here.

Abstract

Background: Epilepsia partialis continua (EPC) is defined as continuous myoclonic jerking of a body part of cortical origin and often resembles a movement disorder. Unfortunately, anti-epileptic therapy is frequently ineffective. Currently, the effect of botulinum neurotoxin (BoNT) therapy in EPC is controversial.

Methods: We analyzed case histories, treatment protocols, and video documentation of 5 patients with EPC, who received BoNT therapy in our movement disorders unit. The Unified Myoclonus Rating Scale was used to document treatment effects.

Results: In all patients, BoNT treatment significantly reduced severity and frequency of myoclonus and led to pronounced improvement of speech and arm utilization, regardless of etiology or duration of EPC.

Conclusion: BoNT represents a safe, effective treatment in EPC, offering long-term abatement of myoclonus. The substantial functional profit may hint at mechanisms beyond local impairment of neuromuscular transmission, such as modulation of maladaptive cortical plasticity, as observed in dystonia and poststroke spasticity.

References

Engel Jr J . A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia. 2001; 42(6):796-803. DOI: 10.1046/j.1528-1157.2001.10401.x. View

Frucht S, Leurgans S, Hallett M, Fahn S . The Unified Myoclonus Rating Scale. Adv Neurol. 2002; 89:361-76. View

Lozsadi D, Hart I, Moore A . Botulinum toxin A improves involuntary limb movements in Rasmussen syndrome. Neurology. 2004; 62(7):1233-4. DOI: 10.1212/01.wnl.0000118283.51400.7a. View

Browner N, Azher S, Jankovic J . Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis. Mov Disord. 2006; 21(9):1500-2. DOI: 10.1002/mds.20991. View

Bien C, Elger C . Epilepsia partialis continua: semiology and differential diagnoses. Epileptic Disord. 2008; 10(1):3-7. DOI: 10.1684/epd.2008.0161. View

Kang J, Krakow K, Roggendorf J, Steinmetz H, Hilker R . Botulinum toxin treatment of epilepsia partialis continua. Mov Disord. 2008; 24(1):141-3. DOI: 10.1002/mds.22185. View

Andrade D, Hamani C, Minassian B . Treatment options for epileptic myoclonus and epilepsy syndromes associated with myoclonus. Expert Opin Pharmacother. 2009; 10(10):1549-60. DOI: 10.1517/14656560903025189. View

Kwan P, Arzimanoglou A, Berg A, Brodie M, Hauser W, Mathern G . Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2009; 51(6):1069-77. DOI: 10.1111/j.1528-1167.2009.02397.x. View

Guerrini R . Physiology of epilepsia partialis continua and subcortical mechanisms of status epilepticus. Epilepsia. 2009; 50 Suppl 12:7-9. DOI: 10.1111/j.1528-1167.2009.02356.x. View

10.

Dijk J, Tijssen M . Management of patients with myoclonus: available therapies and the need for an evidence-based approach. Lancet Neurol. 2010; 9(10):1028-36. DOI: 10.1016/S1474-4422(10)70193-9. View

11.

Dresel C, Bayer F, Castrop F, Rimpau C, Zimmer C, Haslinger B . Botulinum toxin modulates basal ganglia but not deficient somatosensory activation in orofacial dystonia. Mov Disord. 2011; 26(8):1496-502. DOI: 10.1002/mds.23497. View

12.

Benecke R . Clinical relevance of botulinum toxin immunogenicity. BioDrugs. 2012; 26(2):e1-9. PMC: 3683397. DOI: 10.2165/11599840-000000000-00000. View

13.

Hallett M, Albanese A, Dressler D, Segal K, Simpson D, Truong D . Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013; 67:94-114. DOI: 10.1016/j.toxicon.2012.12.004. View

14.

Huynh W, Krishnan A, Lin C, Vucic S, Katrak P, Hornberger M . Botulinum toxin modulates cortical maladaptation in post-stroke spasticity. Muscle Nerve. 2013; 48(1):93-9. DOI: 10.1002/mus.23719. View

15.

Bittner S, Simon O, Gobel K, Bien C, Meuth S, Wiendl H . Rasmussen encephalitis treated with natalizumab. Neurology. 2013; 81(4):395-7. DOI: 10.1212/WNL.0b013e31829c5ceb. View

16.

Varadkar S, Bien C, Kruse C, Jensen F, Bauer J, Pardo C . Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol. 2014; 13(2):195-205. PMC: 4005780. DOI: 10.1016/S1474-4422(13)70260-6. View

17.

Steve T, Gross D . Alcohol-responsive epilepsia partialis continua. Epileptic Disord. 2014; 16(1):107-11. DOI: 10.1684/epd.2014.0626. View

18.

Obeso J, Rothwell J, Marsden C . The spectrum of cortical myoclonus. From focal reflex jerks to spontaneous motor epilepsy. Brain. 1985; 108 ( Pt 1):193-24. DOI: 10.1093/brain/108.1.193. View

19.

Thomas J, Reagan T, KLASS D . Epilepsia partialis continua. A review of 32 cases. Arch Neurol. 1977; 34(5):266-75. DOI: 10.1001/archneur.1977.00500170020003. View

20.

JUUL-JENSEN P, Denny-Brown D . Epilepsia partialis continua. Arch Neurol. 1966; 15(6):563-78. DOI: 10.1001/archneur.1966.00470180003001. View